| Bioactivity | Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS). Thymectacin is an aryloxy phosphoramidate derivative of BVdU (brivudin)[1][2]. |
| Invitro | Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS)[1]. |
| Name | Thymectacin |
| CAS | 232925-18-7 |
| Formula | C20H23BrN3O9P |
| Molar Mass | 560.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wilson RH. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist. 2006;11(9):1018-1024. [2]. Congiatu C, et al. Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. J Med Chem. 2006;49(2):452-455. |
Thymectacin
CAS: 232925-18-7 F: C20H23BrN3O9P W: 560.29
Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.